BofA says Gilead investors ‘can’t be totally dismissive’ of proposed CDC cuts
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
Zacks Investment Research on MSN16h
GILD Stock Down on Report of Cut in HIV Prevention Spending
Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...
Zacks Investment Research on MSN13h
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
STAT21h
Biotech stocks get boost from Fed rate outlook
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Johns Hopkins Medicine16h
HIV and AIDS
AIDS (acquired immunodeficiency syndrome) is caused by the human immunodeficiency virus (HIV). This kills or impairs cells of the immune system and progressively destroys the body's ability to fight ...